4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine

Pridopidine (346688-38-8) is being studied as a potential treatment for Huntington’s disease, Parkinson’s disease, and schizophrenia based on its locomotor stabilizing and antipsychotic-like effects.1,2?It was, unusually, able to reverse both hypo- and hyperdopaminergia depending on local dopamine concentrations without inducing catalepsy. This was originally attributed to functional dopamine D2 antagonism with fast on/off kinetics (“dopamine stabilizer”).3?More recent studies have attributed pridopidine’s effects to its being a more potent sigma-1 ligand than a D2 ligand.4,5?Displays neuroprotective/restorative effects6,7?and ameliorates central features of amyotrophic lateral sclerosis pathology8?in a sigma-1-mediated manner

4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine is Off-White Solid

4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine is a new modulator of dopamine neurotransmission. Dopamine is a neurotransmitter in the brain. Drugs that act at central dopamine receptors are commonly used in the treatment of neurologic and psychiatric disorders.

Store at -20°C

1) Pettersson (2010),?Synthesis and Evaluation of a Set of 4-Phenylpiperidines and 4-Phenylpiperazines as D2 Receptor Ligands and the Discovery of the Dopaminergic Stabilizer 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine (Huntexil, Pridopidine, ACR16);?J.Med.Chem.?53?2510 2)?The dopamine stabilizers (S)-(-)-(3-methanesulfonylphenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat;?J.Pharmacol.Exp.Ther.?318?810 3) Dyhring?et al.?(2010)?The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties;?Eur.J.Pharmacol.?628?19 4) Sahlholm (2015)?Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses;?Psychopharmacology (Berl)?232?3443 5)?Sahlholm?et al.?(2013),?The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the?s-1 receptor;?Mol.Psychiatry?18?12 6) Francardo?et al.?(2019),?Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease;?Neurotherapeutics?16?465 7) Ryskamp,?et al.?(2017),?The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease;?Neurobiol.Dis.?97(Pt A)?46 8) Ionescu?et al.?(2019),?Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model;?Cell Death Dis.?10?210